[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Hospitalier Universitaire de Saint Etienne\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":663},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,120,0,25,[9,48,79,111,140,170,194,220,248,273,297,325,348,372,383,410,433,462,484,510,536,564,587,611,634],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100053801","visual-stimulation-through-video-therapy-to-enhance-lower-limb-motor-recovery-after-stroke-100053801",false,"NCT07629674","Visual Stimulation Through Video Therapy to Enhance Lower Limb Motor Recovery After Stroke","Use of Intensive Visual Stimulation Through Video Therapy to Enhance Lower Limb Motor Recovery After Stroke (SIVIMI). A Single-Center Pilot Study Using a Single-Case Experimental Design (SCED)","SI-VI-MI","Inclusion Criteria:\n\n* \\- First or recurrent hemispheric ischemic or hemorrhagic stroke in the subacute or chronic phase (from 1 month to 1 year post-stroke).\n* Currently receiving rehabilitation care in a Physical Medicine and Rehabilitation (PM\\&R) department\n* Able to walk 3 meters back and forth, with or without an assistive device.\n* Provided informed consent, signed jointly with the investigator.\n\nExclusion Criteria:\n\n* \\- Severe hemispatial neglect.\n* Severe spasticity impairing proper positioning (Modified Ashworth Scale \\> 3).\n* Severe general disabling medical conditions.\n* Associated cerebellar syndrome.\n* Major comprehension disorders, psychiatric illness, or cognitive impairments that could interfere with study participation.\n* Participants under full legal guardianship (tutorship).\n* Pregnant or breastfeeding women.","ALL","18 Years","80 Years",{"count":22,"type":23},12,"ESTIMATED","INTERVENTIONAL",[26],"NA","This pilot study evaluates video therapy for lower limb motor recovery after stroke, an approach remains insufficiently documented.\n\nThis single-center pilot study uses a Single-Case Experimental Design (SCED) to evaluate the effects of intensive video therapy combined with conventional rehabilitation in patients with subacute or chronic post-stroke hemiparesis. Twelve participants will be included and allocated to different baseline durations according to a multiple-baseline SCED design.\n\nThe primary outcome is functional mobility, assessed using the Timed Up and Go (TUG) test, measured repeatedly throughout baseline, intervention, and follow-up phases.",[29],"Hemiparetic Stroke",[31,32,33,34],"Videotherapy","Lower limb rehabilitation","Hemiplegic\u002FHemiparetic","Single case experimental design","RECRUITING","2026-07-10",{"date":38,"type":39},"2026-07-13","ACTUAL",{"date":41,"type":39},"2026-07-09",{"date":43,"type":23},"2028-06-30",{"name":45,"class":46},"Centre Hospitalier Universitaire de Saint Etienne","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":12,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":24,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":47},"100645023","association-between-chronic-kidney-disease-stage-and-circulating-fgf23-cleavage-intensity-in-patients-with-chronic-kidney-disease-100645023","NCT07676526","Association Between Chronic Kidney Disease Stage and Circulating FGF23 Cleavage Intensity in Patients With Chronic Kidney Disease","CLIFF","Inclusion Criteria:\n\n* MRC stage 3a-5 based on the most recent GFR measurement\n* Patient enrolled in or eligible for a social security program\n* Patients who have received informed consent regarding the study and have given their verbal consent to participate\n\nExclusion Criteria:\n\n* Active cancer or a history of cancer in remission for less than 5 years, or a history of cancer in remission for more than 5 years with specific oncological treatment still ongoing.\n* Participation in another study related to treatments for the disease\n* Patients under legal guardianship (legal guardianship or conservatorship)","MALE","55 Years","75 Years",{"count":59,"type":23},80,[26],"This cross-sectional proof-of-concept study aims to investigate the relationship between chronic kidney disease (CKD) severity and circulating FGF23 cleavage intensity estimated by the iFGF23\u002FcFGF23 ratio. Eighty male patients aged 55-75 years with CKD stages 3a to 5 will be included (20 per stage). Blood samples obtained during routine nephrology care will be supplemented by two additional tubes to measure iFGF23, cFGF23, hepcidin, erythropoietin, 1,25-vitamin D and TRAP5b. The primary endpoint is the iFGF23\u002FcFGF23 ratio. Secondary analyses will evaluate the associations between FGF23 forms and renal, hematological, iron metabolism and mineral bone parameters. This study will provide the first human data on FGF23 cleavage alterations across CKD stages and may identify novel biomarkers for anemia and cardiovascular complications.",[63],"CKD - Chronic Kidney Disease",[65,66,67,68,69],"CKD","FGF23","iFGF23\u002FcFGF23 ratio","iron metabolism","anemia","NOT_YET_RECRUITING","2026-06-24",{"date":73,"type":39},"2026-06-30",{"date":75,"type":23},"2026-09",{"date":77,"type":23},"2027-05",{"name":45,"class":46},{"id":80,"slug":81,"hasResults":12,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":12,"sex":18,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":24,"phases":90,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},"100622211","impact-of-mind-body-therapies-hypnosis-and-relaxation-on-anxiety-in-children-adolescents-and-young-adults-who-had-been-treated-in-oncology-multicenter-study-100622211","NCT07380672","IMpact of Mind-body Therapies (HYpnosis and Relaxation) on Anxiety in Children, Adolescents and Young Adults Who Had Been Treated in ONcology. Multicenter Study.","HARMONY-Impact","Inclusion Criteria:\n\nHARMONY KIDS\n\n* Patients aged at least 7 and under 15 at the time of inclusion, diagnosed with pediatric cancer,\n* Patients considered to be in complete remission from pediatric cancer, whose intensive treatment ended at least 3 months prior to inclusion\n* Patients receiving follow-up care after pediatric cancer at one of the participating centers,\n* Patients with anxiety disorders (SCARED-R score ≥ 31)\n* Patients affiliated with or eligible for social security,\n* Patients and their parents (or legal guardians) who have received informed consent about the study and co-signed, with the investigator, a consent form to participate in the study.\n\nHARMONY AYA\n\n* Patients aged at least 15 and no more than 25 years old at the time of inclusion, diagnosed with pediatric cancer before the age of 18,\n* Patients considered to be in complete remission from pediatric cancer, whose intensive treatment ended at least 3 months prior to inclusion,\n* Patients receiving follow-up care after pediatric cancer at one of the participating centers,\n* Patients with anxiety disorders (HADS-Anxiety score ≥ 8)\n* Patients affiliated with or eligible for social security,\n* For adult patients: patients who have received informed information about the study and have co-signed, with the investigator, a consent form to participate in the study,\n* For minors: patients and their parents (or legal guardians) who have received informed consent about the study and have co-signed, with the investigator, a consent form for participation in the study.\n\nExclusion criteria:\n\nFor HARMONY-Kids:\n\n* Presence of active suicidal ideation and\u002For need for urgent psychiatric care,\n* Patient experiencing a cancer relapse,\n* Refusal to participate,\n* Pregnant women, women in labor, or breastfeeding mothers,\n* Individuals deprived of their liberty, hospitalized without consent, or hospitalized for purposes other than research,\n* Individuals subject to legal guardianship or conservatorship, or those unable to give informed consent\n\nFor HARMONY-AYA:\n\n* Presence of active suicidal ideation and\u002For need for urgent psychiatric care,\n* Patients experiencing a cancer relapse,\n* Refusal to participate,\n* Pregnant women, women in labor, or breastfeeding mothers,\n* Individuals deprived of their liberty, hospitalized without consent, or hospitalized for purposes other than research,\n* Adults subject to legal guardianship or conservatorship, or unable to give informed consent.","7 Years","25 Years",{"count":89,"type":23},558,[26],"In France today, it is estimated that one in 850 people aged between 20 and 45 has been cured of cancer in childhood. Some descriptive studies have established that cancer diagnosis and treatment can affect psychological health, with an increased risk of depression, post-traumatic stress, anxiety and suicidal risk. A French study published by our team in 2015 and 2020 also showed that, as adults, 40% of former pediatric cancer patients experienced symptoms of anxiety, a rate significantly higher than that of the general French population (25%).\n\nWhile it is well established that it is essential to detect the onset of anxiety-depressive disorders and, if necessary, to set up conventional psychological treatment (CPT), few studies have sought to show the benefit of complementing this conventional CPT with mind-body therapies (MBT) in the post-cancer pediatric setting.\n\nThis project aims to determine the benefit of mind-body therapies (hypnosis and relaxation) as a complement to conventional psychological treatment (CPT) in the management of anxiety in children, adolescents and young adults in remission from pediatric cancer or leukemia.",[93,94,95],"Adolescent Cancer Survivors","Childhood Cancer Survivors","Anxiety",[97,98,99,100,101],"childhood cancer survivor","anxiety","depression","psychology","body mind therapy","2026-06-17",{"date":104,"type":39},"2026-06-18",{"date":106,"type":23},"2026-09-02",{"date":108,"type":23},"2028-07-01",{"name":45,"class":46},7,{"id":112,"slug":113,"hasResults":12,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":12,"sex":18,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":24,"phases":122,"briefSummary":123,"conditions":124,"keywords":128,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":47},"100641641","use-of-the-single-port-robotic-system-in-pediatric-surgery-100641641","NCT07660497","Use of the Single Port Robotic System in Pediatric Surgery","SPCHIRPED","Inclusion Criteria:\n\n* Aged between 10 and 17 inclusive for the first five and between 1 and 17 for the next five\n* Parents or guardians affiliated with or entitled to social security\n* Patient and legal representative of the patient who has received informed information about the study and has signed the consent form for the child's participation in the study.\n* Patients seen in paediatric surgery consultations at Saint-Etienne University Hospital\n* Patient requiring abdominal surgery such as pyeloplasty, vesicoureteral reflux or gastro-oesophageal reflux\n\nExclusion Criteria:\n\n* History of haemorrhagic disease\n* History of multiple abdominal surgeries (as intraperitoneal adhesions can make surgical access difficult)\n* Pregnant adolescents\n* Patients with electronic implants (e.g. pacemakers).\n* Parents or guardians under guardianship or trusteeship.","1 Year","17 Years",{"count":121,"type":23},10,[26],"Open surgery (laparotomy) has long been the gold standard for pediatric surgery. The development of laparoscopy in the 1980s reduced post-operative pain. Since the 2000s, robotic surgery has been on the rise. The most commonly used robotic system is the Xi robotic system (Intuitive Surgical), which allows instruments to be inserted through three or four trocars and replicates the movements of the surgeon's hands as they sit at a control console a few meters away from the patient.The Single Port (SP) robotic system is a new development in this technology. It allows the same procedures to be performed using a single trocar instead of four. CE marking was obtained in 2024 for abdominal surgery, but without provision for use in children. The pediatric surgery team at Saint-Etienne University Hospital has been performing robotic surgery using the Xi (Intuitive) system since January 2020. Between January 2020 and April 2025, 150 patients underwent surgery, including 49 pyeloplasties, 42 ureterovesical reimplantations, and 23 gastroesophageal reflux treatments. No conversions were necessary, and there were no complications related to the use of the robotic system. The Saint-Etienne University Hospital was the first institution in France to acquire the SP robotic system.",[125,126,127],"Robotic System","Pediatric","Surgery in Children",[129,130,131],"Single Port Robotic System","Pediatric surgery","Access Port","2026-06-16",{"date":134,"type":39},"2026-06-22",{"date":136,"type":39},"2025-11-14",{"date":138,"type":23},"2026-12-15",{"name":45,"class":46},{"id":141,"slug":142,"hasResults":12,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":24,"phases":150,"briefSummary":153,"conditions":154,"keywords":156,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},"100642240","phase-1-a-multicenter-study-of-belantamab-mafodotin-and-mezigdomide-in-patients-with-relapsed-multiple-myeloma-100642240","NCT07612787","A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma","A Multicenter Phase 2 Study of Belantamab Mafodotin and Mezigdomide in Combination With a Phase Ib Safety Run in Patients With Relapsed Multiple Myeloma Following BCMA-targeting CAR-T Cells or Bispecific Antibodies","BELAMI","Inclusion Criteria:\n\n* Subjects who are ≥ 18 years of age\n* Participant has a histologically or cytologically confirmed diagnosis of MM as defined by IMWG criteria\n* Participant has Eastern Cooperative Oncology Group (ECOG) performance status of score of 0, 1, or 2\n* Participant is considered transplant ineligible or for participants with a history of autologous stem cell transplant (ASCT), ASCT was \\>100 days before initiating study treatment\n* Participant has measurable disease with at least one of the following criteria:\n\n  * Serum M protein \\>0.5 g\u002FdL (\\>5 g\u002FL), or\n  * Urine M protein \\>200 mg\u002F24h, or\n  * Serum free light chain (FLC) assay: Involved FLC level \\>5 mg\u002FdL (\\>50 mg\u002FL) and an abnormal serum FLC ratio (\\\u003C0.26 or \\>1.65)\n* Participant is quadruple-class exposed or refractory (anti-CD38 antibody (e.g., daratumumab, isatuximab) alone or in combination, immunomodulatory agent (e.g., lenalidomide, pomalidomide), a proteasome inhibitor (e.g., bortezomib, ixazomib, carfilzomib) and BCMA-directed CAR-T cells and\u002For anti-BCMA bispecific antibodies) and has failed at least 3 prior lines of anti-myeloma therapies\n* Documented presence of BCMA.\n* All prior treatment related toxicities (defined by NCI-CTCAE Version 5.0) must be Grade ≤1 at the time of enrollment, except for alopecia and Grade 2 hematological, hepatic and renal laboratory values.\n* Participant must have adequate organ function at minimum, defined in Table 2 \"adequate organ function\".\n* Life expectancy of at least 6 months, in the opinion of the investigator\n* Sex and Contraceptive\u002FBarrier Requirements\n* Participants must adhere to contraceptive guidelines on contraception methods in clinical studies to minimize the risk of pregnancy\n* Signed informed consent\n* Participant affiliated to or a beneficiary of a social security category\n\nExclusion Criteria:\n\n* Patients under guardianship or curators\n* Patients with insufficient proficiency in French to understand the study information\n* Prior treatment with an anti-BCMA targeted therapy within 90 days of receiving the first dose of study drugs, or treatment with an investigational agent or approved systemic anti-myeloma therapy (including systemic steroids) within 14 days or 5 half-lives of receiving the first dose of study drugs.\n* A known intolerance or immediate or delayed hypersensitivity to drugs chemically related to Belantamab mafodontin or Mezigdomide or any of of the components of the study treatment.\n* Prior treatment with an antibody-drug conjugate.\n* Prior treatment with Mezigdomide.\n* Prior allogeneic stem cell transplant.\n* Any major surgery within 4 weeks before the first dose of study drug (or 2 weeks if clinically stable). Additional exception allowed for bone-stabilizing surgery after consultation with medical monitor.\n* Has received a live or attenuated vaccine within 30 days before the first dose of study treatment.\n* Participant has received plasmapheresis ≤ 7 days before the first dose of study treatment.\n* Presence of active renal condition (infection, requirement for dialysis, or any other condition that could affect participant's safety).\n* Any serious and\u002For unstable pre-existing medical, psychiatric disorder, or other conditions (including lab abnormalities) that could interfere with participant's safety, obtaining informed consent, or compliance with the study procedures.\n* Evidence of active mucosal or internal bleeding.\n* Cirrhosis or current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice.\n* Evidence of cardiovascular risk.\n* Participant has malignancies other than MM are excluded, except for any other malignancy from which the participant has been disease free for \\>5 years with the exception of the following noninvasive malignancies: basal or squamous cell skin carcinoma, carcinoma in situ of the cervix, carcinoma in situ of the breast, incidental histological findings of prostate cancer (T1a or T1b using the tumor, nodes, and metastases clinical staging system), or prostate cancer that is curative.\n* Active infection requiring antibiotic, antiviral, or antifungal therapy.\n* Symptomatic amyloidosis, active POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma-proliferative disorder, skin changes) or active plasma cell leukemia at the time of screening.\n* Current corneal epithelial disease, except mild punctuate keratopathy.\n* Contact lenses are not allowed for participants while they are receiving Belantamab mafodontin treatment. Contact lens use may be restarted after discontinuation of Belantamab mafondontin treatment, provided the eye-care specialist confirms there are no other contraindications.\n* Treatment with strong CYP3A4\u002F5 modulators or Potassium-Competitive Acid Blockers or Proton Pump Inhibitors or unable to absorb oral therapies (i.e. gastric surgery).\n* Participant is a pregnant or lactating female.\n* Participant with known HIV infection is excluded, unless the specific criteria (see relative section) are met.\n* Patient with a presence of hepatitis B surface antigen (HbsAg) or hepatitis B core antibody (HbcAb) at screening or within 3 months before first dose of study treatment should be excluded, unless the criteria described in the relative section are met.\n* Participant with a positive hepatitis C antibody test result or positive hepatitis C RNA test result at screening or within 3 months before first dose of study treatment are excluded, unless the criteria described in the relative section are met.",{"count":149,"type":23},44,[151,152],"PHASE1","PHASE2","The BELAMI trial is an open label, multicenter, phase 2 study for patients with MM who relapsed following BCMA-directed CAR-T cells or bispecific antibodies with a Phase Ib Safety run-in.\n\nThe primary hypothesis of this study is that a combination of ADC targeting BCMA and CELMoD will be efficient for these patients.",[155],"Myeloma Multiple",[157,158,159,160],"cancer","hematology","relapse","antibody","2026-06-11",{"date":163,"type":39},"2026-06-15",{"date":165,"type":23},"2026-06-01",{"date":167,"type":23},"2031-01-01",{"name":45,"class":46},30,{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":24,"phases":179,"briefSummary":180,"conditions":181,"keywords":183,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":187,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":193},"100641849","clinical-evaluation-of-sensory-neuronopathies-the-neuronoscore-study-100641849","NCT07651540","Clinical Evaluation of Sensory Neuronopathies: the Neuronoscore Study","NEURONOSCORE","Inclusion Criteria:\n\n* Patient affiliated with or beneficiary of a social security system\n* Patient having received appropriate study information\n* Adult patient ≥18 years old, male or female\n* Patient diagnosed with probable SN according to Camdessanché et al. diagnostic criteria\n* SN with one of the following etiologies:\n\nParaneoplastic SN with anti-Hu or anti-CV2\u002FCRMP5 antibodies SN associated with Sjögren's syndrome, systemic lupus erythematosus, or primary biliary cholangitis Platinum-salt-induced SN SN caused by CANVAS syndrome\n\nExclusion Criteria:\n\n* Patient unable to understand or read French\n* Patient refusal to participate\n* Patient known to have another neuropathy phenotype and\u002For etiology that could significantly influence clinical scales and electrophysiological parameters, including:\n\n  * Diabetes mellitus\n  * Significant alcohol consumption\n  * Severe chronic kidney disease (GFR \\\u003C30 ml\u002Fmin)\n  * Vitamin B12 and\u002For vitamin E deficiency\n  * Vitamin B6 excess\n  * Chemotherapy other than platinum salts\n  * HIV infection",{"count":178,"type":23},70,[26],"Sensory neuronopathies (SN) are a group of rare neuropathies characterized by selective destruction of sensory neurons located in the dorsal root ganglia. SN may result from a wide range of etiologies, particularly paraneoplastic, autoimmune, toxic, and genetic causes. The functional prognosis of patients with SN is generally poor: in a recent study, two-thirds of patients had a modified Rankin Scale (mRS) score ≥3 and nearly half had an mRS ≥4.\n\nThe absence of reliable biomarkers in neuropathies justifies the use of clinical scales as indicators of disease severity, disability, and treatment response. However, none of the currently available \"general neuropathy\" scales have been specifically designed or validated for SN. The only scale developed specifically for SN is the SEARS (Sensory Ataxia Rating Scale), proposed in 2019, but it has not been widely used nor validated in large populations.\n\nAs a result, the absence of a clinical scale specifically designed for patients with SN makes longitudinal follow-up more challenging, particularly when assessing the response to immunomodulatory or immunosuppressive treatments when these therapies are indicated.",[182],"Sensory Neuronopathy",[184,185,186],"neurology","specific scale","rare neuropathy",{"date":132,"type":39},{"date":189,"type":23},"2026-06-25",{"date":191,"type":23},"2028-06-25",{"name":45,"class":46},19,{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":202,"targetDuration":4,"studyType":24,"phases":204,"briefSummary":205,"conditions":206,"keywords":208,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":47},"100643651","innovative-sleep-quality-analysis-software-compared-with-polysomnography-100643651","NCT07628959","Innovative Sleep Quality Analysis Software Compared With Polysomnography","Pilot Study of Innovative Sleep Quality Analysis Software Compared With Polysomnography","LUNA","Inclusion Criteria:\n\n* Adult patients aged over 18 years.\n* Patients affiliated with or beneficiaries of a social security system.\n* Patients capable of completing all aspects of the study.\n* Patients who have signed informed consent for participation in the study\n\nExclusion Criteria:\n\n* pregnancy\n* Patients suffering from an acute bacterial, fungal, or viral infection.\n* Patients unable to tolerate the placement of the PSG.\n* Patients with psychiatric disorders incompatible with the constraints associated with the need to spend two nights at the clinic.\n* restless legs syndrome\n* Presence of a cardiac pacemaker.\n* Cardiac arrhythmia problems (e.g., complete arrhythmia).\n* Known and treated sleep disorders (e.g., sleep apnea syndrome) or uncontrolled chronic insomnia.\n* Diagnosed dementia.\n* Simultaneous participation in other research studies.\n* Use of medications that could alter sleepiness, including:\n* Sedative-hypnotics.\n* Neuroleptics.\n* Antidepressants.\n* Anxiolytics.\n* H1 antihistamines.\n* Antiepileptics.\n* Opiates and opioid analgesics.\n* Patients under legal guardianship or curatorship.",{"count":203,"type":23},33,[26],"To diagnose sleep disorders, practitioners primarily use polysomnography (PSG), a precise but costly, cumbersome method that is limited to a single observation. This does not allow for longitudinal monitoring of sleep habits in real-world conditions. An alternative is offered with the C. Santé software receiving information from sensors installed on medical bed. This software analyzes cardiorespiratory parameters and sleep phases without disturbing the patient, enabling continuous and comfortable monitoring. A preliminary study aims to validate the reliability of the C. Santé software analysis, by comparing it to the PSG analysis, considered the gold standard.",[207],"Sleep Disorder (Disorder)",[209,210,211],"polysomnography","BCG","Sleep Disorders","2026-06-08",{"date":214,"type":39},"2026-06-10",{"date":216,"type":23},"2026-06",{"date":218,"type":23},"2026-12",{"name":45,"class":46},{"id":221,"slug":222,"hasResults":12,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":228,"sex":229,"minAge":230,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":24,"phases":234,"briefSummary":235,"conditions":236,"keywords":238,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":245,"leadSponsor":247,"locationsCount":47},"100642995","effects-of-a-multimodal-and-multidimensional-intervention-on-urinary-incontinence-in-young-nulliparous-female-athletes-100642995","NCT07644273","Effects of a Multimodal and Multidimensional Intervention on Urinary Incontinence in Young Nulliparous Female Athletes.","Effects of a Multimodal and Multidimensional Intervention on Urinary Incontinence in Young Nulliparous Female Athletes. Single-Center Randomized Controlled Stepped-Wedge Trial","PELVICATHLE","Inclusion Criteria :\n\n* Female subject, nulliparous\n* Member of an athletics club affiliated with the French Athletics Federation (FFA)\n* At least 15 years old at the start of the study and belonging to the U16\u002FU18\u002FU20\u002FU23 categories (born between January 1, 2005, and September 1, 2011)\n* Having internet access\n* Having access to a digital device (computer, tablet, mobile phone)\n* Affiliated with or covered by a social security scheme\n* Having freely given their express consent, as well as the express consent of both parents for minor participants\n\nExclusion Criteria :\n\n* Any individual deprived of their liberty or subject to legal protection (guardianship, curatorship, or protective supervision).\n* A pregnant woman, a woman who has been pregnant, or a woman planning a pregnancy within the last nine months.\n* Any individual unable to understand the purpose and conditions of the study.\n* Any individual unable to give their consent.",true,"FEMALE","15 Years","40 Years",{"count":233,"type":23},198,[26],"A prevalence of urinary incontinence ranging from 5.7% to 80% has been observed in young nulliparous athletes during their activity.\n\nThe usual recommendations for managing adult women do not seem to be transferable.\n\nYoung nulliparous athletes need specific educational and behavioral interventions and an alternative to pelvic floor muscle strengthening.\n\nA multimodal and multidimensional intervention for athletes and coaches combining specific pelvic health education and strengthening of lumbopelvic-abdominal stability appears to be an innovative and optimal solution for reducing the symptoms of urinary incontinence in young nulliparous women who participate in athletics.",[237],"Urinary Incontinence",[239,240,241],"Urinary incontinence","women's health","track and field",{"date":243,"type":39},"2026-06-12",{"date":75,"type":23},{"date":246,"type":23},"2027-06",{"name":45,"class":46},{"id":249,"slug":250,"hasResults":12,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":253,"eligibilityCriteria":254,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":24,"phases":257,"briefSummary":258,"conditions":259,"keywords":261,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":266,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":272},"100499246","impact-of-an-intervention-integrating-the-mphs-nursing-model-of-care-on-the-partnership-in-health-with-the-patient-followed-in-primary-care-by-an-advanced-practice-nurse-apn-for-one-or-more-stabilized-chronic-pathologies-100499246","NCT05780762","Impact of an Intervention Integrating the MPHS Nursing Model of Care on the Partnership in Health, With the Patient Followed in Primary Care by an Advanced Practice Nurse (APN) for One or More Stabilized Chronic Pathologies","IMPACT","Inclusion Criteria:\n\n* A patient receiving care from an advanced practice nurse (APN) for the management of one or more of the following chronic conditions: stroke; chronic arterial disease; heart disease, coronary artery disease; type 1 diabetes and type 2 diabetes; chronic respiratory failure; Parkinson's disease; epilepsy.\n* Care provided by an IPA falls under one of the following categories:\n\nEither as direct care when the IPA practices within a healthcare facility, in accordance with current regulations, Or as care referred or prescribed by a physician when the IPA practices in private practice.\n\n* Affiliated or entitled to a social security plan\n* Having received informed information about the study and having co-signed, with the investigator, a consent to participate in the study\n\nExclusion Criteria:\n\n\\- A patient who is not under the care of a nurse practitioner under the conditions set forth in the Public Health Code (lack of authorized direct access or a required physician referral, depending on the practice model).",{"count":256,"type":23},420,[26],"The WHO and our governance advocate that health professionals should organize care around the patient, considering his or her values, needs and preferences, and enabling the patient to develop the capacity to self-manage the chronic health problems he or she faces. Chronic disease is an ongoing dynamic process and adaptation to this process is complicated by the interaction of several determinants: self-management capacity, level of health literacy, quality of life and experience of care. To best support chronic disease, the recommendation is to adopt a management strategy that allows chronic patients to play an active role in the management of their condition and in the day-to-day decision-making process. The management of chronic pathologies is one of the specialties in which Advanced Practice Nurses are positioned, in primary care, outside hospital. Nursing care benefits from care models that allow for more adapted responses, regarding particular care situations, or certain patient typologies. The Humanistic Partnership Health Care Model (MPHS) implement in current Advanced Practice Nurse (APN) practice.",[260],"Chronic Disease",[262,263,264,265],"advanced practice nurse (APN)","patient partnership","health literacy","self-management",{"date":214,"type":39},{"date":268,"type":39},"2024-04-12",{"date":270,"type":23},"2028-11-30",{"name":45,"class":46},5,{"id":274,"slug":275,"hasResults":12,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":281,"targetDuration":4,"studyType":24,"phases":282,"briefSummary":283,"conditions":284,"keywords":286,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":296,"locationsCount":47},"100617647","insole-optimization-for-rheumatoid-arthritis-patients-100617647","NCT07321340","Insole Optimization for Rheumatoid Arthritis Patients","Insole Optimization for Rheumatoid Arthritis Patients - INORA - (Insole Optimization for Rheumatoid Arthritis Patients)","INORA","Inclusion Criteria:\n\n* Patients with rheumatoid arthritis according to 2010 ACR\u002FEULAR criteria\n* RA at low activity level according to DAS28≤3.2\n* Patient with mechanical forefoot involvement on walking and improved by foot orthoses.\n\nExclusion Criteria:\n\n* Patients with a contraindication to a bone scan\n* Patients with neurological gait disorders that interfere with gait analysis\n* Exclude particularly protected persons:\n\n  * Pregnant women, parturients, nursing mothers;\n  * Persons deprived of liberty, hospitalized without consent, hospitalized for purposes other than research;\n  * Minors;",{"count":121,"type":23},[26],"Rheumatoid arthritis affects 0.5% of the population, often leading to foot deformities and pain that are difficult to treat. Management is based on controlling inflammation, adapting footwear and using custom-made insoles, all of which have proven effective. The aim of this research is to build a digital model of plantar pressures based on CT scans, in order to optimize orthopedic insoles. The study will analyze the gait of patients with and without standard insoles to identify mechanical criteria correlated with pain. The ultimate aim is to design optimized insoles, validated by a new gait analysis.",[285],"Rhumatoid Arthisis",[287,288,289],"Insole","Rheumatoid arthritis","Feet","2026-06-04",{"date":292,"type":39},"2026-06-05",{"date":294,"type":39},"2026-06-02",{"date":218,"type":23},{"name":45,"class":46},{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":228,"sex":18,"minAge":304,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":24,"phases":306,"briefSummary":307,"conditions":308,"keywords":311,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":324},"100643540","validation-of-a-remediation-method-for-memory-impairments-through-motor-encoding-in-patients-with-alzheimers-disease-100643540","NCT07632755","Validation of a Remediation Method for Memory Impairments Through Motor Encoding in Patients With Alzheimer's Disease","ADACT","Inclusion Criteria:\n\nPatient group: Diagnosis of Alzheimer's disease made by one of the consulting physicians-a neurologist and\u002For geriatrician (Dubois et al., 2014)-at the early stage, presenting with mild memory impairment of which the patient has been informed\n\n\\- MMSE score of 21 or higher\n\nControl group: individuals without a diagnosis of Alzheimer's disease, but meeting the other criteria listed below\n\n* Enrollment in a social security program\n* Age 60 or older\n* French as a native language\n* Consent to participate\n\nExclusion Criteria:\n\n* Uncorrected visual or hearing impairments\n* Language or motor impairments\n* Delirium or psychosis.\n* Medical treatment affecting vision, language, or motor skills (or participation in a study involving a drug or device that influences cognition).\n* Refusal to participate.\n* Inability to communicate\n* Persons deprived of liberty by a judicial or administrative decision and adults subject to a legal protection measure or unable to express their consent","60 Years",{"count":59,"type":23},[26],"In France, over 1.5 million people suffer from mild cognitive impairment, often a precursor to Alzheimer's disease (AD), whose global prevalence could reach 153 million by 2050. With no curative treatment available, maintaining patients' autonomy at home is essential to mitigate the negative effects of institutionalization and reduce economic costs. Non-pharmacological approaches, such as cognitive training, have shown potential in stabilizing cognitive functions. Research suggests that motor networks and procedural memory remain relatively preserved in early AD, and bodily engagement during encoding enhances memory. For patients with motor impairments, motor imagery (MI) activates these networks without actual movement. Additionally, dynamic visual cues, like videos, reduce cognitive load compared to static images. This project aims to combine real action, MI, and dynamic visual supports to optimize memory. By validating 120 videos of daily activities, it will assess the impact of action on recall, evaluate MI's effectiveness for patients with mobility limitations, and confirm the superiority of videos over static images. The results could support the development of digital tools, such as serious games, to enhance patients' autonomy and address aging-related challenges.",[309,310],"Alzheimer s Disease","Healhty",[312,313,314,315,316,317],"Alzheimer's disease","memory remediation","motor-enriched encoding","imagery","static imagery","dynamic imagery",{"date":212,"type":39},{"date":320,"type":23},"2026-06-20",{"date":322,"type":23},"2028-06",{"name":45,"class":46},3,{"id":326,"slug":327,"hasResults":12,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":24,"phases":335,"briefSummary":336,"conditions":337,"keywords":340,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":343,"startDateStruct":344,"completionDateStruct":345,"leadSponsor":347,"locationsCount":47},"100643673","study-of-proteomic-factors-in-patients-with-severe-dry-eye-syndrome-treated-with-autologous-serum-eye-drops-100643673","NCT07632534","Study of Proteomic Factors in Patients With Severe Dry Eye Syndrome Treated With Autologous Serum Eye Drops.","Study of Proteomic Factors in Patients With Severe Dry Eye Syndrome Treated With Autologous Serum Eye Drops. Single-center Study.","Prot-CSA","Inclusion Criteria:\n\n* Age over 18 years\n* Patients with severe dry eye with an Oxford score \\> 1\n* Patients with dry eye syndrome refractory to conventional treatments: tear substitutes, immunosuppressive eye drops or corticosteroids.\n* AS-naïve patients followed by an ophthalmologist at Saint-Etienne University Hospital\n* Patients affiliated to or entitled under a social security scheme\n* Patients who have received informed information about the study\n\nExclusion Criteria:\n\n* Severe ocular dryness due to a genetic disease\n* Patients not under the care of an ophthalmologist at Saint-Etienne University Hospital.\n* Patients not eligible for treatment with AS (pregnant women, anaemia, current infection, progressive disease, serological results contraindicating blood sampling).\n* Patients under protective measures",{"count":334,"type":23},68,[26],"Dry eye syndrome is a multifactorial pathology of the ocular surface. Epidemiological studies report a prevalence of 15% in adults aged between 50 and 95. Depending on the severity of the disease, different treatment strategies may be proposed. The use of autologous serum eye drops (AS) represents an interesting therapeutic alternative for the most severe forms of the disease, due to the serum's composition, which is similar to that of tears. The mechanism of action of AS is still controversial, but is probably multifactorial and seems to be based on growth factors, vitamin factors and anti-inflammatory factors. The clinical response of patients could be dependent on the protein composition of the eye drops. The investigators are aiming to highlight a difference in serum protein composition that could explain the differences in clinical response between patients treated with autologous serum eye drops and to identify the proteins that would be involved in a clinical response or non-response.",[338,339],"Dry Eye Syndrome (DES)","Dry Eye",[341,342],"autologous serum eye drops","dry eye disease",{"date":212,"type":39},{"date":216,"type":23},{"date":346,"type":23},"2028-12",{"name":45,"class":46},{"id":349,"slug":350,"hasResults":12,"nctId":351,"briefTitle":352,"officialTitle":352,"acronym":353,"eligibilityCriteria":354,"healthyVolunteers":228,"sex":18,"minAge":87,"maxAge":355,"enrollmentInfo":356,"targetDuration":4,"studyType":24,"phases":358,"briefSummary":359,"conditions":360,"keywords":362,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":294,"lastUpdatePostDateStruct":366,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":47},"100640837","the-extraordinary-endurance-of-the-human-species-100640837","NCT07626593","The Extraordinary Endurance of the Human Species","0 TO 100","Inclusion Criteria:\n\n* Affiliation to social security.\n* Informed consent signed.\n* Male or female, aged 25-50.\n* Sedentary (\\>6h\u002Fday sitting) and inactive (no regular training), assessed by GPAQ questionnaire.\n\nExclusion Criteria:\n\n* Chronic joint or cardiac diseases.\n* Neurological disorders.\n* Legal protection status.\n* Moderate to severe depression (BDI-13 \\> 7) or use of antidepressants\u002Fanxiolytics.\n* Use of banned substances.\n* Excessive alcohol or caffeine consumption.\n* Pregnancy.\n* Inability to understand or consent.","50 Years",{"count":357,"type":23},40,[26],"We hypothesize, based on field and scientific data, that setting a very ambitious goal such as completing a mountain ultra-marathon could motivate sedentary and inactive individuals not only to begin training but also to follow a progressive yet extremely ambitious program that has not yet been studied comprehensively. Indeed, the effects of intense and prolonged endurance training (18 months) on the health and performance of completely sedentary individuals have never been investigated exhaustively.",[361],"Healthy Volunteers",[363,364,365],"Ultra-endurance","Sedentary","Healthy volunteers",{"date":290,"type":39},{"date":368,"type":39},"2026-02-03",{"date":370,"type":23},"2027-11",{"name":45,"class":46},{"id":373,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":374,"targetDuration":4,"studyType":24,"phases":375,"briefSummary":27,"conditions":376,"keywords":377,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":378,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":382,"locationsCount":47},"100639977",{"count":22,"type":23},[26],[29],[31,32,33,34],{"date":292,"type":39},{"date":380,"type":23},"2027-02-01",{"date":43,"type":23},{"name":45,"class":46},{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":389,"eligibilityCriteria":390,"healthyVolunteers":228,"sex":18,"minAge":19,"maxAge":391,"enrollmentInfo":392,"targetDuration":4,"studyType":24,"phases":394,"briefSummary":395,"conditions":396,"keywords":399,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":403,"startDateStruct":405,"completionDateStruct":407,"leadSponsor":409,"locationsCount":47},"100617719","effects-of-exercise-timing-on-sleep-quality-100617719","NCT07322276","Effects of Exercise Timing on Sleep Quality","Effects of Exercise Timing and Physical Activity Level on Sleep Quality and Body Temperature","SLEEPCORE","Inclusion Criteria:\n\n* Group \"Inactive\" :No regular exercise practice (inactive people that don't follow the WHO recommendations) and have sedentary behaviors\n* Group \"Active\": Regular exercise (athletes that are specialized in aerobic exercise, with more than 300 minutes per-week over 6 months and practice at regional level).\n\nExclusion Criteria:\n\n* Have sleep disorders medically diagnosed or detected by sleep forms cutoffs (clinical insomnia by ISI, severe risk of obstructive sleep apnea by Stop-Bang, bad sleep quality by PSQI.\n* Have a diagnosed mental health condition requiring treatment\n* Have renal, respiratory, cardiovascular or neuromuscular disease medically diagnosed.\n* Be pregnant or breastfeeding","30 Years",{"count":393,"type":23},42,[26],"Modern lifestyles are marked by a prevalence of sedentary behaviors and physical inactivity, which have been linked to numerous adverse health effects. While regular physical exercise is a well-established countermeasure, exercising in the late afternoon may paradoxically disrupt deep sleep due to increased core body temperature. Inactive and sedentary individuals, who often have impaired autonomic function compared to endurance-trained athletes, may be particularly susceptible to these negative effects, potentially resulting in compromised thermoregulation and exacerbated disruptions to deep sleep, a critical stage of sleep essential for overall recovery. Therefore, this study aims to investigate the impact of aerobic exercise performed in the late afternoon versus morning on: 1) deep sleep and sleep onset latency; and 2) core body temperature and its autonomic regulatory mechanisms on endurance-trained and inactive-sedentary people.",[397,398],"Healthy Endurance Athlet","Inactive People",[400,401,402],"endurance athletes","exercise timing","sleep quality",{"date":404,"type":39},"2026-06-03",{"date":406,"type":39},"2026-01-23",{"date":408,"type":23},"2029-05-31",{"name":45,"class":46},{"id":411,"slug":412,"hasResults":12,"nctId":413,"briefTitle":414,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":418,"targetDuration":4,"studyType":24,"phases":420,"briefSummary":421,"conditions":422,"keywords":424,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":427,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":110},"100543035","phase-2-therapeutic-effect-of-hydroxychloroquine-on-immunoglobulin-a-iga-nephropathy-course-quigan-study-100543035","NCT06350630","Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study","Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA)Nephropathy Course QUIgAN Study","QUIgAN","Inclusion Criteria:\n\n* Social security affiliation\n* Signed informed consent\n* With biopsy proven IgA nephropathy (any vintage)\n* With at least one Oxford lesion (M, E, S, T, C) on last available kidney biopsy - With urine albumin\u002Fcreatinine \\> 300mg\u002Fg,\n* under maximal tolerated labeled dose of renin-angiotensin-aldosterone system (RAAS) inhibitors for at least 3 months\n* Sodium-Glucose Transport Protein 2 (SGLT-2) inhibitors initiated at least 1 month before inclusion visit\n* Only patients treated with SGLT2i and RAAS dual therapy before inclusion\n* With estimate GFR above 15 mL\u002Fmin\u002F1,73m² (Chronic Kidney Disease - EPIdemiology collaboration CKD-EPI formula)\n* Woman in childbearing with a highly effective method of contraception\n* Agreement of woman in childbearing potential (WOCBP) to perform a urine pregnancy test every month until three months after the end of study treatment\n* Agreement of fertile male with WOCBP partner to use a condom for the duration of the study treatment up to 3 months after treatment the end of study treatment.\n\nExclusion Criteria:\n\n* Secondary IgA nephropathy (Henoch Schonlein purpura, cirrhosis, inflammatory bowel disease)\n* Corticosteroid or immunosuppressive therapies in the past year before screening\n* Contra-indication to hydroxychloroquine (retinopathy, maculopathy, history of intolerance to hydroxychloroquine…)\n* Uncontrolled hypertension (systolic blood pression\\> 160 mmHg and\u002For diastolic blood pression \\>110 mmHg )\n* Long QT interval and\u002For QT prolonging medicines\n* Pregnancy or lactation",{"count":419,"type":23},334,[152],"immunoglobulin A (IgA) nephropathy (Berger disease) is the most frequent primary glomerulonephritis worldwide. This disease accounts for about 5% of the causes of end stage renal disease in France, representing a major public health issue. Its pathophysiology seems to be triggered by mucosal immunity abnormalities leading to the systemic misaddressing of mucosal IgA, generation of circulating immunoglobulin A1 (IgA1) immune complexes finally deposited in renal glomeruli leading to renal tissue inflammation and scarring processes. Among this pathogeny, innate immunity is involved at several steps, including mucosal immunity.\n\nIn this regard, hydroxychloroquine has been shown to generate a global anti-inflammatory effect, particularly through its action on Toll like receptors and dendritic cells. This drug is well tolerated, widely used for other auto-immune diseases (e.g. Systemic Lupus Erythematosus) and very low priced.\n\nOne randomized controlled study conducted in China has recently shown a significant drop in proteinuria of IgA nephropathy patients treated with hydroxychloroquine (-48.4%) compared to the placebo group (+10.0%), after a quite short-term follow-up (6 months) and a moderate statistical power (30 patients in each group).\n\nConsidering (i) the potential mechanism of therapeutic effect on this disease, (ii) the well documented safety profile of the drug for rheumatologic indications and posologies, and its low cost (iii) its efficacy in reducing proteinuria in IgA nephropathy patients in a preliminary Chinese randomized control study, the investigators aim in this study at establishing the beneficial impact of hydroxychloroquine on IgA nephropathy in a double blind randomized controlled trial on a Caucasian French population with harder outcomes and a longer follow-up compared to the Chinese preliminary study.",[423],"IgA Nephropathy",[425,426],"Hydroxychloroquine","proteinuria",{"date":404,"type":39},{"date":429,"type":39},"2025-06-26",{"date":431,"type":23},"2030-12-31",{"name":45,"class":46},{"id":434,"slug":435,"hasResults":12,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":439,"eligibilityCriteria":440,"healthyVolunteers":228,"sex":18,"minAge":441,"maxAge":442,"enrollmentInfo":443,"targetDuration":4,"studyType":24,"phases":444,"briefSummary":445,"conditions":446,"keywords":450,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":454,"lastUpdatePostDateStruct":455,"startDateStruct":457,"completionDateStruct":459,"leadSponsor":461,"locationsCount":47},"100594563","muscle-vibration-as-a-countermeasure-against-hypoactivity-induced-100594563","NCT07021079","Muscle Vibration as a Countermeasure Against Hypoactivity-induced","Effects of Focal Muscle Vibration as a Countermeasure Against Hypoactivity-induced Neuromuscular Deconditioning","NEUROVIB-ULLS","Inclusion Criteria:\n\n* Men and women.\n* Aged 18 to 45 years.\n* Body Mass Index (BMI) between 18,5 and 24,9 kg\u002Fm².\n* Engaging in at least 1.5 hours per week of physical activity (e.g., brisk walking, running, swimming, cycling).\n* Provided informed consent after receiving detailed information about the study.\n* Affiliated with or beneficiaries of a social security system\n\nExclusion Criteria:\n\n* Chronic cardiovascular, neuromuscular, bone, metabolic, and\u002For inflammatory disorders.\n* Personal history and\u002For risk factors for thrombosis.\n* Use of antidepressant medications.\n* Use of neuroactive substances likely to alter corticospinal excitability (e.g., hypnotics, antiepileptics, psychotropics, muscle relaxants) during the study.\n* Recent bone or ligament trauma within the past 12 months.\n* Inability to perform the physical efforts required for the study.\n* Recent participation in a sporting competition or intense, unusual physical activity within the past month.\n* Corticosteroid treatment within the past 3 months.\n* Any skin lesions at the planned vibrator application site.\n* Simultaneous participation in another interventional medical study.\n* Pregnant or breastfeeding women.\n* Individuals unable to understand the purpose and conditions of the study or unable to provide informed consent.\n* Individuals deprived of liberty or under guardianship","19 Years","45 Years",{"count":393,"type":23},[26],"Muscle deconditioning, characterized by a loss of muscle mass and strength, is a frequent consequence of prolonged lower limb unloading. Beyond muscle mass loss, reduced neural drive contributes significantly to strength decline, highlighting the need for interventions targeting neuromuscular function during immobilization. Focal muscle vibration (FMV) has shown promise in modulating neuromuscular excitability by activating muscle spindle afferents and inducing cortical adaptations. Chronic use of FMV has been associated with significant strength gains and improved neural command. This makes FMV an effective rehabilitation tool. Its simplicity and non-invasiveness further make it a practical countermeasure.",[447,448,449],"Vibration Therapy","Healthy Volunteer Study","Hypoactivity",[451,452,453],"hypoactivity","neuromuscular deconditionning","Vibration","2026-05-22",{"date":456,"type":39},"2026-05-26",{"date":458,"type":39},"2025-06-16",{"date":460,"type":23},"2027-08-31",{"name":45,"class":46},{"id":463,"slug":464,"hasResults":12,"nctId":465,"briefTitle":466,"officialTitle":466,"acronym":467,"eligibilityCriteria":468,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":469,"targetDuration":4,"studyType":24,"phases":471,"briefSummary":472,"conditions":473,"keywords":475,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":480,"completionDateStruct":481,"leadSponsor":483,"locationsCount":272},"100634386","effect-of-descemet-membrane-polishing-in-fuchs-endothelial-corneal-dystrophy-100634386","NCT07539012","Effect of Descemet Membrane Polishing in Fuchs Endothelial Corneal Dystrophy","Fuchs Polishin","Inclusion Criteria:\n\n* Patient affiliated with or entitled to a social security scheme\n* Patient scheduled for endothelial keratoplasty for Fuchs endothelial corneal dystrophy\n* Patient having received full information and having provided written informed consent\n\nExclusion Criteria:\n\n* Pregnant women\n* Adults under legal protection (guardianship\u002Fcuratorship) or unable to provide informed consent",{"count":470,"type":23},20,[26],"Fuchs endothelial corneal dystrophy (FECD) is the leading indication for corneal transplantation worldwide. It is characterized by the accumulation of guttae and progressive loss of corneal endothelial cells, leading to corneal edema and visual impairment. Endothelial keratoplasty remains the standard treatment; however, graft shortages have driven the development of cell-based therapies involving the injection of cultured endothelial cells. A key unresolved issue is whether removal of the pathological endothelium prior to injection improves cell adhesion. Clinical data are limited and sometimes contradictory, particularly regarding endothelial polishing. The actual effectiveness of this procedure in removing guttae and enhancing the survival of injected cells remains uncertain. Therefore, an in vivo clinical evaluation is required to assess its impact on guttae removal.",[474],"Fuchs Endothelial Corneal Dystrophy",[474,476,477],"Corneal endothelial polishing","Ophtalmic therapeutics","2026-05-21",{"date":456,"type":39},{"date":478,"type":39},{"date":482,"type":23},"2027-03-01",{"name":45,"class":46},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":488,"acronym":489,"eligibilityCriteria":490,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":24,"phases":493,"briefSummary":494,"conditions":495,"keywords":497,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":503,"lastUpdatePostDateStruct":504,"startDateStruct":506,"completionDateStruct":507,"leadSponsor":509,"locationsCount":47},"100634745","objective-assessment-of-skin-damage-using-adhelaskin-in-patients-with-systemic-sclerosis-100634745","NCT07543679","Objective Assessment of Skin Damage Using ADHELASKIN in Patients With Systemic Sclerosis","OBSKINS","Inclusion Criteria:\n\n* Patients affiliated with or eligible for social security\n* Patients who have received informed consent about the study and have co-signed, with the investigator, a consent form to participate in the study\n* For case patients: Patients with SSc according to the 2013 ACR\u002FEULAR criteria\n* For control patients: Patients without significant skin involvement\n\nExclusion Criteria:\n\n* Persons deprived of their liberty, hospitalized without consent, hospitalized for purposes other than research;\n* Adults subject to legal protection measures (guardianship-curatorship) or unable to express their consent\n* Inflammatory or scarring dermatoses in different individuals",{"count":492,"type":23},100,[26],"Systemic sclerosis (SSc) is an autoimmune disease characterized by skin fibrosis, which clinically manifests as thickening, hardening, and loss of elasticity of the skin. Patients are typically classified as having diffuse cutaneous SSc (dcSSc) or limited cutaneous SSc (lcSSc) depending on the extent of skin fibrosis. The standard assessment of cutaneous sclerosis is based on the modified Rodnan skin score (mRSS), which consists of clinical palpation of 17 areas of the body, scored from 0 (normal) to 3 (severe sclerosis) for each area, with a total of 51 points.\n\nHowever, the mRSS has several limitations, including high inter- and intra-observer variability, particularly depending on the clinician's experience, subjectivity of palpation with difficulties in quantifying subtle changes in firmness or elasticity, and limited sensitivity to small changes or in areas that are not severely affected. The assessment of skin fibrosis therefore faces a lack of objective, quantitative tools that are easy to use in routine clinical practice. Certain alternatives have been evaluated (durometer, ultrasound, elastography, etc.), but none has yet been fully adopted or validated for measuring firmness, elasticity, and adhesion at different depths of the skin with good accuracy and reproducibility.\n\nADHELASKIN° technology (by Tactinnov, LTDS \u002F École Centrale de Lyon) enables objective, highly sensitive measurement of rigidity, firmness and elasticity using an indentation method with a ruby ball sensor. The objective of our study is to assess whether the ADHELASKIN device can differentiate between the biomechanical properties of healthy patients and those of patients with SSc.",[496],"D013493",[498,499,500,501,502],"Systemic sclerosis","firmness","skin evaluation","Rodnan score","mRSS","2026-05-07",{"date":505,"type":39},"2026-05-12",{"date":503,"type":39},{"date":508,"type":23},"2027-05-01",{"name":45,"class":46},{"id":511,"slug":512,"hasResults":12,"nctId":513,"briefTitle":514,"officialTitle":515,"acronym":516,"eligibilityCriteria":517,"healthyVolunteers":12,"sex":18,"minAge":518,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":24,"phases":520,"briefSummary":521,"conditions":522,"keywords":524,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":47},"100581068","purine-supplementation-in-patients-with-aica-ribosiduria-100581068","NCT06845501","Purine Supplementation in Patients With AICA-Ribosiduria","PURICA : Purine Supplementation in Patients With AICA-Ribosiduria","PURICA","Inclusion Criteria:\n\n* Individual affected by AICA-ribosiduria due to ATIC deficiency\n\nExclusion Criteria:\n\n\\- Individual already on a purine-rich diet theoretical contraindication to a purine-rich diet","3 Years",{"count":121,"type":23},[26],"AICA-Ribosiduria due to ATIC deficiency is a rare genetic metabolic disease that affects less than 10 patients (PMID: 32557644). It results in severe polyhandicap linked to neurodevelopmental disorders, visual impairment, growth retardation, severe spinal deformities and scoliosis, and often early-onset epilepsy. The disease is caused by dysfunction of the ATIC enzyme, which is involved in de novo purine biosynthesis. A recent study (PMID: 38244287) reported a decrease in disease biomarkers in a single patient after 3 months on a purine-rich diet, which persisted for at least 1 year. The investigators propose to replicate this study on several patients to investigate the potential of this treatment for this severe orphan disease.",[523],"AICA-ribosiduria Due to ATIC Deficiency",[525,526,527],"AICA-Ribosiduria","ATIC","purine","2026-05-05",{"date":530,"type":39},"2026-05-08",{"date":532,"type":39},"2025-04-24",{"date":534,"type":23},"2029-05",{"name":45,"class":46},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":540,"acronym":541,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":18,"minAge":543,"maxAge":4,"enrollmentInfo":544,"targetDuration":4,"studyType":24,"phases":545,"briefSummary":546,"conditions":547,"keywords":551,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":556,"startDateStruct":558,"completionDateStruct":560,"leadSponsor":562,"locationsCount":563},"100559296","evaluation-of-the-reproducibility-of-a-fatigability-test-fitted-to-patients-with-spinal-muscular-atrophy-100559296","NCT06562283","Evaluation of the Reproducibility of a Fatigability Test Fitted to Patients With Spinal Muscular Atrophy","FANTASI-SMART","Inclusion Criteria:\n\n* Genetically confirmed spinal muscular atrophy\n* Age ≥ 6 years\n* No orthopaedic surgery in the 6 months prior to inclusion\n* Informed consent signed by the patient(s) or parent(s)\u002Flegal guardian(s) and assent of the patient\n* Affiliated or beneficiary of a health insurance scheme (for inclusion in France)\n\nExclusion Criteria:\n\n* Other condition that may significantly interfere with the assessment of the SMA and which is clearly unrelated to the disease\n* Other associated neurological disease\n* Joint deformities that prevent correct and comfortable positioning with the various different measuring devices (thumb-index clamp, handgrip and QIF-test)\n* Contraindication to transcranial magnetic stimulation","6 Years",{"count":59,"type":23},[26],"Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disease caused by the degeneration of motor neurons in the anterior horn of the spinal cord, due to the absence of the SMN1 gene and the resulting lack of SMN protein. Some patients with particularly severe forms (types 0 or 1) die before the age of 2 in the absence of treatment, while others retain autonomous walking throughout their lives, with no reduction in life expectancy. Three treatments aimed at restoring SMN (TRS) protein expression have recently been approved by the US Food and Drug Administration and the European Medicines Agency (i.e. Nusinersen \u002F Onasemnogene Abeparvovec \u002F Risdiplam). Patients treated with TRS after the onset of symptoms (symptomatic patients) may show significant motor improvement, but retain difficulties such as muscle weakness and fatigue leading to limitations in activities of daily living. The aim of this study is to adapt a fatigability test, widely validated in its original version in different populations (QIF test), but adapted in this protocol to the motor level and low abilities of certain SMA patients. Our objectives are to determine whether these assessments are feasible in SMA patients, reproducible, and relevant for monitoring this population, either routinely or for future clinical trials.",[548,549,550],"Spinal Amyotrophy","Infantile Spinal Muscular Atrophy","Juvenile Spinal Muscular Atrophy",[552,553,554,555],"Spinal Muscle Atrophy","Neuromuscular performance","Fatigue","Peripheral fatigue",{"date":557,"type":39},"2026-05-06",{"date":559,"type":39},"2024-12-06",{"date":561,"type":23},"2026-10",{"name":45,"class":46},4,{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":568,"acronym":569,"eligibilityCriteria":570,"healthyVolunteers":228,"sex":229,"minAge":391,"maxAge":571,"enrollmentInfo":572,"targetDuration":4,"studyType":24,"phases":574,"briefSummary":575,"conditions":576,"keywords":578,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":582,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":586,"locationsCount":47},"100535670","evaluation-of-first-void-urine-as-an-alternative-to-cervical-sampling-for-human-papillomavirus-hpv-testing-in-cervical-cancer-screening-single-center-study-100535670","NCT06254846","Evaluation of First-void Urine as an Alternative to Cervical Sampling for Human Papillomavirus (HPV) Testing in Cervical Cancer Screening (Single-center Study).","URAPREV","Inclusion Criteria:\n\n* Female\n* Age between 30 and 65\n* Consulting in the Gynecology-Obstetrics department for primary cervical cancer screening\n* Patient affiliated or entitled to a social security regimen\n* Patient who has received information about the study and expressed non-opposition\n\nExclusion Criteria:\n\n\\-","65 Years",{"count":573,"type":23},350,[26],"Papillomaviruses are responsible for almost all cervical cancers. In France, there are more than 3000 new cases of cervical cancer each year and nearly 1000 deaths. One of the ways to prevent this cancer is screening by PCR on cervical sample for which national coverage rate remains very insufficient (\\\u003C60%). The invasive and uncomfortable nature of cervical sampling has been identified as a major obstacle to screening. In this context, an alternative sample, such as the first-void urine, seems to be judicious. Nevertheless, some studies have shown a lack of sensitivity of the HPV PCR test on urine. As underlined by the French National Authority for Health (HAS), this is mainly due to a lack of standardization of urine collection. In this study, the investigators therefore propose to evaluate the performance of the HPV PCR test on first-void urine using a standardized protocol. Through a questionnaire, they will also evaluate the acceptability of the first void urine collection device.",[577],"Uterine Cervical Cancer",[579,580,581],"HPV","Cervical cancer","Cancer screening",{"date":557,"type":39},{"date":584,"type":39},"2024-05-23",{"date":77,"type":23},{"name":45,"class":46},{"id":588,"slug":589,"hasResults":12,"nctId":590,"briefTitle":591,"officialTitle":592,"acronym":593,"eligibilityCriteria":594,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":595,"targetDuration":4,"studyType":24,"phases":597,"briefSummary":598,"conditions":599,"keywords":601,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":605,"startDateStruct":606,"completionDateStruct":608,"leadSponsor":610,"locationsCount":47},"100529197","transcutaneous-vagus-nerve-stimulation-as-a-complementary-therapy-to-exercise-in-chronic-fatigue-100529197","NCT06170645","Transcutaneous Vagus Nerve Stimulation as a Complementary Therapy to Exercise in Chronic Fatigue","Transcutaneous Vagus Nerve Stimulation as a Complementary Therapy to Exercise in Chronic Fatigue: Single-center, Controlled, Randomized, Blinded Study","PAF-tVNS","Inclusion Criteria:\n\n* Patient over 18 years old\n* Signature of informed consent\n* Confirmed diagnosis of fibromyalgia or long Covid (ACR 2016 criteria and persistent symptoms lasting more than 6 months after a positive RT-PCR test, respectively)\n* Persistent fatigue after an exercise rehabilitation program (FSS score \\> 36)\n* Physical inactivity, i.e. \\\u003C150 minutes per week of physical activity\n\nExclusion Criteria:\n\n* Pre-existing atrial fibrillation,\n* Left ventricular ejection fraction \\\u003C40%\n* Severe heart failure\n* Recent stroke or myocardial infarction (\\\u003C6 months)\n* Unilateral or bilateral vagotomy\n* Pregnancy or breastfeeding",{"count":596,"type":23},60,[26],"Chronic fatigue is enhanced by adapted physical activity (APA) programs. Patients consulting on St Etienne hospital and suffering from fibromyalgia and long Covid benefit from a 4-6 week APA program, with 2 sessions per week. While most patients are improved by these exercise-training programs, for some the benefits remain very modest, and patients describe persistent fatigue. The literature unanimously describes the necessity of longer APA protocols (8-12 weeks, 2-3 sessions\u002Fweek) for fatigue reduction in fibromyalgia and long Covid. However, it seems difficult to adhere to an optimal program as described in the literature for these fatigued patients. The investigators want to test a device that would both reduce fatigue and improve recovery between APA sessions, in order to gradually reach the recommendations for APA practice. Transcutaneous vagal nerve stimulation (tVNS) seems to be a promising approach. Thus, combining an APA intervention with a tVNS protocol could potentiate the expected and now well-known effect of exercise.",[600],"Chronic Fatigue Syndrome",[602,603,604],"Chronic fatigue","Transcutaneous vagal nerve stimulation (tVNS)","adapted physical activity (APA)",{"date":557,"type":39},{"date":607,"type":39},"2024-10-03",{"date":609,"type":23},"2028-08",{"name":45,"class":46},{"id":612,"slug":613,"hasResults":12,"nctId":614,"briefTitle":615,"officialTitle":616,"acronym":617,"eligibilityCriteria":618,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":619,"targetDuration":4,"studyType":621,"phases":4,"briefSummary":622,"conditions":623,"keywords":625,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":628,"startDateStruct":629,"completionDateStruct":631,"leadSponsor":633,"locationsCount":47},"100496291","analysis-of-the-genotypephenotype-relationship-in-the-fuchs-corneal-endothelial-dystrophy-in-france-100496291","NCT05742321","Analysis of the Genotype\u002FPhenotype Relationship in the Fuchs' Corneal Endothelial Dystrophy in France","Analysis of the Genotype\u002FPhenotype Relationship in the Fuchs' Corneal Endothelial Dystrophy in France. The French Fuchs' Follow-up Study (Phase 2), F3S2","F3S2","Inclusion Criteria:\n\n* affiliated with or entitled to a social security scheme\n* Consent form to participate in the study signed\n* with an FECD certified by slit lamp examination\n* requiring an endothelial keratoplasty\n\nExclusion Criteria:\n\n\\- Patients under guardianship or curators",{"count":620,"type":23},500,"OBSERVATIONAL","The pathophysiology of the most common corneal endothelial dystrophies (Fuchs' Corneal Endothelial Dystrophy, FECD) is beginning to be dismembered. There is a significant heterogeneity in the clinical forms and the investigators have just highlighted a great diversity of histological forms that seem to define distinct groups.",[624],"Corneal Dystrophies",[624,626,627],"Corneal Endothelial Dystrophy","Fuchs' Corneal Endothelial Dystrophy, FECD",{"date":557,"type":39},{"date":630,"type":39},"2024-08-08",{"date":632,"type":23},"2026-09-01",{"name":45,"class":46},{"id":635,"slug":636,"hasResults":12,"nctId":637,"briefTitle":638,"officialTitle":638,"acronym":639,"eligibilityCriteria":640,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":641,"targetDuration":4,"studyType":24,"phases":643,"briefSummary":645,"conditions":646,"keywords":648,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":657,"startDateStruct":658,"completionDateStruct":660,"leadSponsor":661,"locationsCount":662},"100487460","phase-3-best-antithrombotic-therapy-in-patients-with-acute-venous-thromboembolism-while-taking-antiplatelets-100487460","NCT05627375","Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets","BAT-VTE","Inclusion criteria\n\n* Signed informed consent\n* Patients with acute objectively confirmed symptomatic proximal deep-vein thrombosis (DVT) or pulmonary embolism (PE) (with or without deep-vein thrombosis). Proximal deep-vein thrombosis is defined as thrombosis involving at least the popliteal vein or a more proximal vein of the lower limb.\n* Indication of full-dose anticoagulant therapy for at least 3 months.\n* Prescription of antiplatelet therapy for secondary prevention of atherosclerotic cardiovascular diseases, at the time of VTE diagnosis\n* Life expectancy more than 3 months\n* Social security affiliation\n\nExclusion Criteria:\n\n* Unable to give informed consent\n* Active bleeding or a high risk of bleeding contraindicating anticoagulant treatment; a systolic blood pressure of more than 180 mm Hg or a diastolic blood pressure of more than 110 mm Hg\n* Anticoagulation for more than 5 days prior to randomization\n* Active pregnancy or expected pregnancy or no effective contraception\n* Isolated distal deep vein thrombosis\n* Antiplatelet therapy prescribed for primary prevention of cardiovascular disease\n* Indication to maintain a dual-antiplatelet therapy.\n* Triple positive antiphospholipid syndrome, with arterial thrombosis\n* Major cardiovascular and cerebrovascular event in the past 12 months for acute coronary syndrome, and in the past 6 months for cerebrovascular diseases and peripheral arterial diseases",{"count":642,"type":23},1400,[644],"PHASE3","Venous thromboembolism (VTE) and atherosclerotic cardiovascular disease share common risk factors and frequently coexist in the same patients.\n\nTheir management requires use of antithrombotic agents: anticoagulant therapy (AC) for secondary prevention of VTE recurrence, antiplatelet (AP) for secondary prevention of major adverse ischemic cardiovascular and cerebrovascular event (MACCE) in patients with atherosclerotic cardiovascular disease (coronary artery disease, atherosclerotic cerebrovascular disease, lower extremity peripheral arterial disease).\n\nSide effects of antithrombotic drugs are the 1st cause of emergency admission and hospitalization for an adverse drug reaction (mainly bleeding), and the combination of AC with AP strongly increases this risk.",[647],"Venous Thromboembolic Disease",[649,650,651,652,653,654,655,656],"deep venous thrombosis","pulmonary embolism","anticoagulant","antiplatelet","Venous Thromboembolism","Direct oral anticoagulants","major adverse ischemic cardiovascular and cerebrovascular event","secondary prevention",{"date":530,"type":39},{"date":659,"type":39},"2023-08-16",{"date":346,"type":23},{"name":45,"class":46},28,""]